Trial record 7 of 7 for:    FMR1

Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
David Hessl, MD, University of California, Davis
ClinicalTrials.gov Identifier:
NCT00879515
First received: April 9, 2009
Last updated: March 5, 2013
Last verified: March 2013
  Purpose

By testing physiological responses to anxiety in people with nervous system developmental disorders, this study will identify specific physiological characteristics associated with response to anxiety treatments.


Condition
Anxiety Disorders
Child Developmental Disorders, Pervasive

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Genetics and Physiology of Social Anxiety in Fragile X

Resource links provided by NLM:


Further study details as provided by University of California, Davis:

Primary Outcome Measures:
  • Fear-potentiated startle reflex [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Saliva samples collected at four time periods


Enrollment: 511
Study Start Date: October 2005
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Males and females with fragile X syndrome, ages 5 to 25 years old
2
Males and females with the FMR1 premutation, ages 5 to 25 year old
3
Males and females with Down syndrome, ages 5 to 25 years old
4
Males and females with normal development, ages 5 to 25 years old

Detailed Description:

Anxiety is a common and significant problem for people suffering from disorders of nervous system development, including fragile X syndrome. There are few validated treatments for anxiety in people with these disorders, in part because the biological basis of anxiety in neurodevelopmental disorders has not been clearly described. This study will evaluate the physiological responses of people with fragile X syndrome, Down syndrome, and the fragile X premutation (a mild version of the genes that cause fragile X syndrome) to a variety of sensory, emotional, and social stimuli. By analyzing the data collected for this study, researchers aim to identify physiological characteristics linked to subgroups within the disorders, demonstrate links between physiological responses and behavioral or psychiatric symptoms, and measure physiological changes in people receiving treatment for their disorders.

Participation in this study will include one testing session, which will take between 3 and 3.5 hours. Participants who receive treatment for their anxiety may be asked to complete this testing a second time, after their treatment. During the testing session, sensors will be placed on participants' skin in several locations to measure heart rate, sweat response, and eye-blinks. Participants will then be asked to respond to multiple stimuli: sounds, lights, smells, pictures that elicit different types of emotions, an interaction with an unfamiliar person, and specialized toys. In addition, participants will undergo blood testing and have several samples of their saliva collected on the day of the testing session. Participants will also be asked to collect additional saliva samples at home three times a day on 4 different days. Child participants and their parents may also be asked to complete questionnaires and interviews about behavioral and emotional problems.

  Eligibility

Ages Eligible for Study:   5 Years to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Individuals with fragile X syndrome, Down syndrome, the fragile X premutation, and normal development

Criteria

Inclusion Criteria:

  • Fragile X premutation or fragile X syndrome, measured by DNA testing; Down syndrome, confirmed by chromosomal analysis; or normally developing control
  • Normal hearing
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00879515

Locations
United States, California
M.I.N.D. Institute, University of California, Davis
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
  More Information

Additional Information:
No publications provided

Responsible Party: David Hessl, MD, Associate Professor, Principal Investigator, University of California, Davis
ClinicalTrials.gov Identifier: NCT00879515     History of Changes
Other Study ID Numbers: K23 MH077554, K23MH077554, DDTR B2-MBA
Study First Received: April 9, 2009
Last Updated: March 5, 2013
Health Authority: United States: Federal Government

Keywords provided by University of California, Davis:
Fragile X Premutation
Fragile X Syndrome
Down Syndrome

Additional relevant MeSH terms:
Anxiety Disorders
Developmental Disabilities
Down Syndrome
Child Development Disorders, Pervasive
Mental Disorders
Mental Disorders Diagnosed in Childhood
Mental Retardation
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on April 15, 2014